Fujifilm (TSE:4901) said this week it launched the FCT Embrace 85cm wide bore computed tomography imaging unit, touting it as the world’s first such device to hit the market.
The system launch marks the company’s first foray into the CT field, FujiFilm said. The release was announced at the American Society for Radiation Oncology annual meeting ASTRO in San Antonio, Texas.
The FCT Embrace system offers 64 and 128 slice configurations, and is intended for use in both oncology and radiology applications, the Tokyo-based company said. The system offers enhanced CT simulation and radiotherapy treatment planning capabilities, Fujifilm added.
“Fujifilm is a company of ‘firsts’ in diagnostic imaging. In 1936, we took our first steps in the development of X-ray film; and in 1983, we pioneered the first digitized radiography system in the world. Once again we are innovating with the launch of the FCT Embrace, a solution that provides the most slices ever seen on an 85cm bore system. Designed to improve radiation oncology care, this advanced solution boosts patient comfort and security by offering the widest tabletop currently available at 49cm, and accommodating bariatric patients of up to 660lbs,” COO Johann Fernando said in a press release.
Varian Medical (NYSE:VAR) yesterday released details on its development of an artificial intelligence-driven radiotherapy treatment suite the company is designing to incorporate multiple imaging types including magnetic resonance imaging, pulse emission tomography and computed tomography.
The Palo Alto, Calif.-based said that it is developing the suite to improve workflow for clinicians and to improve access to adaptive therapy. The system is also intended to improve communications between physician and patient, and to improve patient monitoring.
“We are creating a treatment suite that includes treatment planning, treatment delivery, and patient monitoring to fuel the next generation of radiation therapy. We are doing this through multimodality imaging available at the console in combination with next generation AI-driven auto-segmentation and treatment planning. We will make use of state of the art treatment delivery including 17-second high-resolution kV iterative cone-beam CT imaging and our advanced multi-leaf collimator design to enable delivery arcs that require just 30-seconds,” Dr. Louis Harrison of the Moffitt Cancer Center said in a prepared statement.
“Based on input from our clinical partners around the world, having MR, PET, and CT imaging all available at the console and utilization of AI automation could transform what they can visualize and adapt. We want to create a streamlined workflow that increases patient access to adaptive therapy even in the busiest clinics,” Varian oncology systems prez Chris Toth said in a press release.
Royal Philips (NYSE:PHG) put its suite of radiation oncology and software systems on display at the ASTRO 2018 meeting.
The portfolio includes a software suite intended to integrate both CT and MR imaging systems, and “represents a significant step forward in supporting improved care, accelerated time to treatment and enhanced patient satisfaction,” according to a press release.
“Care teams are continuously seeking ways to reduce uncertainty during the radiotherapy process and more confidently and efficiently deliver targeted, personalized therapy. Spanning imaging and treatment planning, our new portfolio combines advanced imaging systems with intelligent, adaptive treatment planning software. Through strong, innovative partnerships with our customers and industry partners, Philips is designing dedicated radiation oncology solutions that enhance the work of clinicians and their patient care,” Philips radiation oncology GM Ardie Ermers said in a prepared statement.
Varian Medical this week announced the launch of its Bravos Afterloader system intended for use in high dose rate brachytherapy treatments.
The Palo Alto, Calif.-based company said that the system is designed to improve workflow efficiency and simplify treatment. The system allows the operator to position the radioactive source in the appropriate applicator following a pattern designed to create a conformal dose distribution within or on the surface of the patient’s anatomy.
“We are excited about the capabilities of Bravos and have already begun treating patients in our department. As we continue to use and learn the features in this new system, the clinical efficiencies will enable us to improve our Brachytherapy workflow,” brachytherapy physicist Vicki Currie of Norfolk & Norwich University Hospital said in a prepared release.
“After spending time in clinics around the world talking with the treatment teams, we saw the opportunity to create a system that is easy to use and creates greater efficiencies, allowing clinicians to spend more time with the patient. Bravos is a big step forward for brachytherapy treatments and we will continue to collaborate with our partners in achieving new victories against cancer,” Varian global portfolio solutions VP Ed Vertatschitsch said in a press release.
QFix Positioning this week said it launched a new brachytherapy transfer device for its Symphony patient transport system.
The Avondale, Penn.-based company said its Symphony system is intended for use in setup, positioning and the transfer of patients for procedures using imaging and brachytherapy treatments.
“Symphony provides a simple way to safely improve workflow efficiencies and throughput, enabling centers to treat more patients during a typical day of treatment,” CEO & CTO Dan Coppens said in a prepared statement.
ViewRay (NSDQ:VRAY) this week released details from its investor and analyst meeting at ASTRO 2018 and presented highlighted clinical experiences from uses of its MRIdian Systems.
In a presentation led by Dr. Louis Harrison, the Cleveland-based company spoke of the opportunity for MRI-guided radiotherapy to be used in cancer treatment.
“With MRI-guidance and the ability to adjust dosing during treatment, physicians now have the unmatched ability to personalize and adapt radiotherapy to deliver the highest biologically effective dose to patients while sparing healthy tissue and critical organs. We believe that such an approach has significant potential to improve patient outcomes, especially in cancer than has been historically difficult to treat,” Dr. Harrison said in a press release.
In a second presentation, by Dr. Michael Steinberg of the UCLA David Geffen School of Medicine, the company focused on improved visualization available with MRI-guidance as compared to cone-beam CT.
“The integration of MRI with adaptive radiotherapy represents the next generation in radiation oncology and a potential new standard of care for treating cancer. The patient, clinical and economic benefits associated with MRI-guided radiotherapy make it highly attractive to a multitude of stakeholders,” Dr. Steinberg said in a prepared statement.
The post ASTRO 2018 Roundup: Fujifilm launches FCT Embrace CT unit appeared first on MassDevice.
from MassDevice https://ift.tt/2R7Qcmp
Cap comentari:
Publica un comentari a l'entrada